Comparative Risk of Respiratory Virus Infections Among Patients with Asthma Treated with Biologic Therapies
Clicks: 13
ID: 325816
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
3.6
/100
13 views
12 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #31 of 116 articles by views in qjm : monthly journal of the association of physicians
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Respiratory virus infections are a major cause of morbidity in asthma. Although biologic therapies targeting type 2 inflammation are widely used for severe asthma, their comparative effects on respiratory virus infection risk remain unclear. METHODS: We conducted a retrospective cohort study using the TriNetX US Collaborative Network, including adults with asthma who newly initiated benralizumab, omalizumab, dupilumab, or mepolizumab. Using an active comparator, new-user design with 1:1 propensity score matching, we compared benralizumab with each biologic. The primary outcome was a composite of respiratory virus infections (COVID-19, influenza, RSV infection, and viral pneumonia) over three years. Hazard ratios (HRs) were estimated using Cox proportional hazards models. RESULTS: After matching, 5,663 benralizumab-omalizumab pairs, 7,075 benralizumab-dupilumab pairs, and 6,492 benralizumab-mepolizumab pairs were included. Benralizumab was associated with a higher risk of composite respiratory virus infection than omalizumab (HR 1.49, 95% CI 1.33-1.66), dupilumab (HR 1.24, 95% CI 1.11-1.39), and mepolizumab (HR 1.24, 95% CI 1.12-1.38; all p < 0.001). Risks of COVID-19 and influenza were consistently higher with benralizumab across all comparisons. Viral pneumonia risk was higher versus dupilumab (HR 1.59, 95% CI 1.18-2.14) but not versus omalizumab or mepolizumab. RSV infection risk did not differ significantly. CONCLUSIONS: Benralizumab was associated with a higher risk of respiratory virus infections than omalizumab, dupilumab, and mepolizumab. These findings suggest that profound eosinophil depletion may impair antiviral host defense and should be considered when selecting biologic therapy for patients at increased risk of respiratory viral infections.
| Reference Key |
openalex_W7203879576
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Kuang‐Ming Liao, Sheng Chi Huang, I-Ha Lao, Chia-Yu Kuo, Wan‐Hsuan Hsu, Jheng-Yan Wu, Chih-Cheng Lai |
| Journal | qjm : monthly journal of the association of physicians |
| Year | 2026 |
| DOI |
10.1093/qjmed/hcag218
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.